+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2018

  • ID: 4667857
  • Drug Pipelines
  • November 2018
  • Region: Global
  • 143 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Celon Pharma SA
  • CTI BioPharma Corp
  • Incyte Corp
  • NMS Group SpA
  • MORE
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2018

Summary

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 4, 1, 7 and 3 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Respiratory, Cardiovascular, Central Nervous System, Gastrointestinal, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Myelofibrosis, Alopecia, Atopic Dermatitis (Atopic Eczema), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hematological Tumor, Leukemias, Myeloproliferative Disorders, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Psoriasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma, Asthma, Auto Inflammatory Disease, Autoimmune Disorders, B-Cell Leukemia, Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Prostate Cancer, Myelodysplastic Syndrome, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thalassemia, Ulcerative Colitis, Vitiligo and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Celon Pharma SA
  • CTI BioPharma Corp
  • Incyte Corp
  • NMS Group SpA
  • MORE
Introduction

Report Coverage

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development

Aerie Pharmaceuticals Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Celgene Corp

Celon Pharma SA

CJ HealthCare Corp

Concert Pharmaceuticals Inc

CTI BioPharma Corp

Eli Lilly and Co

Incyte Corp

Japan Tobacco Inc

NMS Group SpA

Novartis AG

NS Pharma Inc

Simcere Pharmaceutical Group

Theravance Biopharma Inc

Tragara Pharmaceuticals Inc

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles

APL-581 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-13503 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1480 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baricitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHZ-868 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-15314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPL-407105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-543 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delgocitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fedratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

jaktinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-2014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NS-018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pacritinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-317461 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Nov 01, 2018: Incyte provides data on ruxolitinib (Jakafi) at the 60th Annual ASH meeting

Nov 01, 2018: With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis

Oct 25, 2018: FDA grants priority review for Ruxolitinib (Jakafi) as a treatment for patients with acute graft-versus-host disease

Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018

Oct 15, 2018: New data showcasing Lilly's growing commitment in Rheumatology to be featured at the ACR/ARHP Annual Meeting

Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018

Oct 01, 2018: CTI BioPharma announces the continuation of PAC203 Study following interim data review

Sep 28, 2018: Concert revises Phase lla trial design to add new CTP-543 dose

Sep 13, 2018: Incyte announces positive data from phase 2b trial of Ruxolitinib cream in patients with atopic dermatitis

Sep 10, 2018: Lilly to Showcase Olumiant new data at the 27th European Academy of Dermatology and Venereology (EADV) Congress, furthering innovation for patients with complex dermatological conditions

Jul 19, 2018: Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)

Jul 18, 2018: CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA

Jul 02, 2018: CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib

Jun 21, 2018: Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi) in Steroid-Refractory Acute Graft-Versus-Host Disease

Jun 21, 2018: Incyte to Present Data on Jakafi at 2018 Investor and Analyst Event

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Aerie Pharmaceuticals Inc, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Celgene Corp, H2 2018

Pipeline by Celon Pharma SA, H2 2018

Pipeline by CJ HealthCare Corp, H2 2018

Pipeline by Concert Pharmaceuticals Inc, H2 2018

Pipeline by CTI BioPharma Corp, H2 2018

Pipeline by Eli Lilly and Co, H2 2018

Pipeline by Incyte Corp, H2 2018

Pipeline by Japan Tobacco Inc, H2 2018

Pipeline by NMS Group SpA, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by NS Pharma Inc, H2 2018

Pipeline by Simcere Pharmaceutical Group, H2 2018

Pipeline by Theravance Biopharma Inc, H2 2018

Pipeline by Tragara Pharmaceuticals Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Dormant Products, H2 2018 (Contd..3), H2 2018

Dormant Products, H2 2018 (Contd..4), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aerie Pharmaceuticals Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Celon Pharma SA
  • CJ HealthCare Corp
  • Concert Pharmaceuticals Inc
  • CTI BioPharma Corp
  • Eli Lilly and Co
  • Incyte Corp
  • Japan Tobacco Inc
  • NMS Group SpA
  • Novartis AG
  • NS Pharma Inc
  • Simcere Pharmaceutical Group
  • Theravance Biopharma Inc
  • Tragara Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll